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Background: Endocannabinoids provide control over cortical neurotransmission. We investigated the
developmental expression of key genes in the endocannabinoid system across human postnatal life and
determined whether they correspond to the development of markers for inhibitory interneurons, which shape
cortical development. We used microarray with qPCR validation and in situ hybridisation to quantify mRNA for
the central endocannabinoid receptor CB1R, endocannabinoid synthetic enzymes (DAGLα for 2-arachidonylglycerol
[2-AG] and NAPE-PLD for anandamide), and inactivating enzymes (MGL and ABHD6 for 2-AG and FAAH for
anandamide) in human dorsolateral prefrontal cortex (39 days - 49 years).
Results: CB1R mRNA decreases until adulthood, particularly in layer II, after peaking between neonates and toddlers.
DAGLα mRNA expression is lowest in early life and adulthood, peaking between school age and young adulthood.
MGL expression declines after peaking in infancy, while ABHD6 increases from neonatal age. NAPE-PLD and FAAH
expression increase steadily after infancy, peaking in adulthood.
Conclusions: Stronger endocannabinoid regulation of presynaptic neurotransmission in both supragranular and
infragranular cortical layers as indexed through higher CB1R mRNA may occur within the first few years of human
life. After adolescence, higher mRNA levels of the anandamide synthetic and inactivating enzymes NAPE-PLD and
FAAH suggest that a late developmental switch may occur where anandamide is more strongly regulated after
adolescence than earlier in life. Thus, expression of key genes in the endocannabinoid system changes with
maturation of cortical function.
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The output of principal cortical neurons is regulated by
a network of inhibitory interneurons [1,2]. Coordinated
development of these neurons underlies the acquisition
and adaptation of visual, motor and cognitive function
throughout postnatal life. Cognitive development during
critical periods such as toddlerhood and adolescence is
characterised by rapid acquisition of executive functions
such as language, goal-directed behaviour and working
memory [3-5]. This development is subserved by pro-
cesses that facilitate a balance between excitatory and in-
hibitory transmission such as synaptogenesis [6-8],
maturation of inhibitory interneurons [9], development* Correspondence: c.weickert@neura.edu.au
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reproduction in any medium, provided the orof GABA receptors [10-12] and an early-life switch from
excitatory to inhibitory actions of GABA [13-15].
The endogenous cannabinoid (endocannabinoid)
system modulates excitatory-inhibitory balance by medi-
ating short- and long-term synaptic plasticity. Cannabin-
oid CB1 receptors (CB1R) are thought to be primarily
localised to presynaptic terminals of inhibitory GABAer-
gic interneurons that express the neuropeptide chole-
cystokinin (CCK) and target the soma or proximal
dendrite of pyramidal neurons in the primate dorsolat-
eral prefrontal cortex (DLPFC) and primate and rodent
hippocampus [16-18]. In addition, CB1Rs have been
shown to co-localise with the calcium-binding proteins
calbindin and calretinin in distinct subsets of cortical in-
hibitory interneurons [16,18-20]. CB1Rs are also loca-
lised to some principal neurons in the hippocampus and
the cerebellar cortex [21-23], although the current con-
sensus is that they are expressed at much lower levelstd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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endocannabinoids signal via a number of other receptors
in addition to CB1 [25], the major mode by which they
interact with CB1Rs is via retrograde signalling. Follow-
ing membrane depolarisation, increased Ca2+ concentra-
tion or metabotropic glutamate receptor activation,
endocannabinoid ligands are synthesised in the postsy-
naptic terminal. Postsynaptic release and retrograde dif-
fusion of endocannabinoids results in presynaptic CB1R
activation and suppression of neurotransmitter release
from presynaptic [20,26-31] and, indirectly, from postsy-
naptic terminals [32].
Biosynthesis of one major endocannabinoid, ananda-
mide, from membrane phospholipid precursors is cata-
lysed by several enzymes. The most well-studied of
these, which we measured the encoding mRNA for here,
is N-acylphosphatidylethanolamine-specific phospholip-
ase D (NAPE-PLD; [33,34]), but others include glycero-
phosphodiesterase (GDE1) [35], abhydrolase domain 4
(ABHD4) [36] and the phosphatase PTPN22 [37]. For-
mation of the other major endocannabinoid, 2-
arachidonylglycerol (2-AG), is catalysed by alpha and
beta diacylglycerol lipases (DAGL) [38]. Fatty acid amide
hydrolase (FAAH) catalyses postsynaptic anandamide
breakdown [39,40] while 2-AG activity is terminated by
both presynaptic monoglyceride lipase (MGL) and the
postsynaptic abhydrolase domain 6 enzyme (ABHD6)
[41-45]. Together, these elements of the endocannabi-
noid signalling system regulate early nervous system de-
velopment (i.e. neuroblast migration [46], pyramidal cell
specification [47], interneuron migration [48] and axon
guidance [49-51]) and synaptic plasticity [29,52], and
thus would also be expected to sculpt behavioural and
cognitive development.
It is thus critical to determine the normal developmen-
tal trajectory of the endocannabinoid system, in humans
and to determine which elements may be changing dur-
ing critical periods such as adolescence, when the major-
ity of cannabis use commences and which may be a
period of vulnerability to the detrimental effects of can-
nabis exposure [53,54]. Indeed, earlier age of cannabis
use onset is associated with higher risk of psychotic
symptoms and neuroanatomical abnormalities associated
with psychosis [55-58]. However, while brain region-
dependent increases and decreases in CB1R binding
density and distribution between prenatal, infant and
adult humans have been described [59-62], detailed
studies of human endocannabinoid system development,
particularly in the frontal cortex, are lacking. The aim of
the present study was therefore to extend these earlier
findings, using gene expression analysis to describe the
development of CB1R and some of the major endocan-
nabinoid metabolic enzyme mRNAs in human DLPFC
across postnatal life. Given the localisation of CB1Rs toCCK-, calbindin- and calretinin-positive interneurons,
we hypothesised that the trajectory of cortical CB1R de-
velopment would partially correspond to those previ-
ously determined for these interneuron marker mRNAs
in the same subjects [9].
Results
Expression of housekeeping gene mRNAs did not
change significantly over the lifespan, nor did the geo-
metric mean of the expression for all four housekeeping
genes (Additional file 1: Figure S1).
CB1R mRNA decreases across postnatal life
Microarray analysis revealed a significant decrease of ap-
proximately 50% in CB1R mRNA (probeset 213436_at)
across the human lifespan (r =−0.779, p < 0.001,
Figure 1A). Expression decreased from a peak in neo-
nates to a plateau from toddler age until adolescence,
and then further decreased to adult levels. qPCR data
showed that CB1R mRNA decreased across postnatal life
and correlated with RIN (r = 0.458, p < 0.001) and PMI
(r = .337, p < 0.01) (ANCOVA, F = 5.5, df = 6, 47,
p < 0.001, Figure 1B). Post-hoc LSD tests showed that
CB1R mRNA peaked in toddlers and was lower in the
adult group than in all other earlier age groups except
young adults (see Figure legend for other group
comparisons).
By in situ hybridisation we found a distinct laminar
pattern of CB1R mRNA hybridisation signal in the grey
matter, although scattered CB1R mRNA-positive signal
was also found below the cortex in the white matter
(small arrows, Figure 2). In the grey matter we found a
dark band of increased CB1R mRNA immediately sub-
adjacent to layer I, corresponding to layer II (large
arrowheads, Figure 2). Another more diffuse band of
increased CB1R mRNA signal was found in deeper cor-
tical layers corresponding to layers V and VI, the width
and intensity of which appeared to vary with age. There
was no hybridisation detectable above background in
sections incubated with the sense strand riboprobe
(Additional file 2: Figure S2). Overall, in situ data indi-
cated that CB1R mRNA expression decreased with age,
particularly in the superficial cortical grey matter. Ana-
lysis of optical density of films generated from in situ hy-
bridisation indicated that in all age groups, CB1R mRNA
expression was highest in the supragranular cortical
layer II (main effect: cortical layer F(5, 205) = 15.1,
p < 0.001; simple contrast of layer II vs all other layers
p < 0.001; Figure 3). Expression was highest in neonates
and infants and lowest in adults, and these differences
were statistically significant in layers II, III, V and VI
(main effect: age group F(6, 41) = 2.54, p < 0.05; inter-
action effect: cortical layer x age F(30, 205) = 1.80,
p < 0.01). Some layer-specific variation in the
Figure 1 CB1R mRNA in developing human DLPFC determined by (A) microarray (y-axis, arbitrary units in log scale) across age (x- axis,
log years) and (B) qPCR [y-axis, mean (+ S.E.M.) expression normalised to the geometric mean of four housekeeping genes] plotted by
age group. * P <0.05, ** P <0.01, *** P <0.001 (ANCOVA and post-hoc LSD).
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superficial layers II and III the school age group showed
less pronounced reduction in CB1R mRNA density than
in other layers; and in layer III only, teenagers showed
significantly higher CB1R mRNA expression than both
toddlers and adults. Silver grain clusters with a scatter
diameter of 8–12 μm, representing the density of CB1R
mRNA per cell, were visible 4–5 times above back-
ground levels on small interneuron-like cells in layers II,
III, IV and VI (large arrowheads, Figure 4A – D). Clus-
ters with a scatter diameter of 10 - 16 μm were visible
on larger cells in layers III, V and VI (small arrows,
Figure 4E - H).
CB1R mRNA levels are not correlated with expression of
the interneuron marker CCK
Expression of CB1R mRNA, as measured by qPCR, was
positively correlated with expression of mRNA for the
interneuron markers calbindin (r = 0.526, p < 0.001) andFigure 2 Representative autoradiograms of CB1R mRNA hybridisation
arrowheads: CB1R mRNA signal in layer II; small arrows: scattered signal in wcalretinin (r = 0.359, p = 0.01; Figure 5A - B). There was
no correlation between CB1R and CCK mRNA
(r = 0.082, p > 0.05; Figure 5C).
2-AG synthesising enzyme mRNA (DAGLα) and
hydrolysing enzyme mRNAs (MGL and ABHD6) show
dynamic, divergent patterns across postnatal life.
Microarray analysis revealed a gradual increase in
DAGLα expression (probeset 214128_at) from low neo-
nate levels to a peak at young adulthood (r = 0.409,
p < 0.01, Figure 6A). qPCR data indicated that DAGLα
expression was significantly correlated with pH
(r = 0.319, p < 0.05). However, due to variability and lim-
ited n, subsequent ANCOVA results showed that
DAGLα expression approached, but did not reach a sta-
tistically significant change across development with our
chosen primer and probes (F = 2.0, df = 6, 48, p = 0.08,
Figure 6B). Based on microarray results, planned post-
hoc LSD tests carried out on the qPCR expression data
showed that compared with both neonates and adults,in each age group of the developing human DLPFC. Large
hite matter.
Figure 3 Mean CB1R mRNA expression in each layer (I – VI) of the developing human DLPFC. Data represent mean (+ S.E.M.). n = 5 – 13.
* P <0.05, ** P <0.01, *** P <0.001 vs. neonate, # P <0.05, ## P <0.01 vs. infant, ^ P <0.05 vs. teenage (post-hoc LSD).
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(p < 0.05), school age (p < 0.01) and teenage individuals
(p < 0.05), indicating a peak at school age.
MGL mRNA expression (probeset 211026_s_at) was
quite variable in the microarray, showing an inverted U-
shaped pattern across the human lifespan with a rapid
increase until 6 months of age and then a steady decline
starting after age 10 (quadratic regression p < 0.05,
Figure 6C). qPCR analysis confirmed the developmental
downregulation of MGL mRNA expression with age
(ANOVA, F = 5.1, df = 6, 47, p < 0.001, Figure 6D), andFigure 4 High power brightfield photomicrographs of CB1R mRNA po
DLPFC. CB1R silver grains (black dots) appear on small interneuron-like cell
arrows). Scale bar = 10 μm.post-hoc LSD tests showed that MGL expression was
significantly reduced from infant levels by school age
and continued to decrease from school age until adult-
hood. However, qPCR data failed to confirm the early in-
crease in MGL mRNA from neonates to infants,
suggesting that the prominent pattern was one of
decline.
Microarray analysis showed that ABHD6 mRNA ex-
pression (probeset 45288_at) increased during human
maturation by around 50% (r = 0.627, p < 0.001,
Figure 6E). By qPCR, we saw a similar pattern, but wesitive cells/nuclei in layers II (A – D) and V (E – H) of the human
s (large arrowheads) and larger pyramidal neuron-like cells (small
Figure 5 Significant correlation of CB1R mRNA expression with mRNA for the interneuron markers calbindin (A) and calretinin (B), but
not cholecystokinin (C).
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over postnatal development and maturation by qPCR,
with a plateau from school age to young adulthood fol-
lowed by an increase to adult levels [ANCOVA, F = 4.1,
df = 6, 49, p = 0.002, Figure 6F; ABHD6 mRNA corre-
lated with pH (r = 0.416, p = 0.001)]. Post-hoc LSD tests
showed increased ABHD6 mRNA expression in all age
groups compared with neonates, and in adults compared
with infants (p < 0.05).
Anandamide synthesising and hydrolysing enzyme mRNAs
(NAPE-PLD and FAAH) increase across postnatal life
Microarray analysis revealed a steady and large increase
of almost 300% in NAPE-PLD mRNA expression (pro-
beset 226041_at) from the neonate to adult groups
(r = 0.959, p < 0.001, Figure 7A). By qPCR, we confirmed
that NAPE-PLD mRNA expression increased steadily
across development [ANCOVA, F = 6.8, df = 6, 45,
p < 0.001, Figure 7B; correlated with PMI (r =−0.367,
p < 0.001)]. Post-hoc LSD tests showed that compared
with neonates NAPE-PLD mRNA expression was signifi-
cantly increased in later life, from an 87% rise in toddlers
to a 106% increase in adults.
FAAH mRNA expression (probeset 204231_s_at) was
not altered across development in the microarray
(r = 0.258, p = 0.09, Figure 7C). qPCR data indicated,
however, that FAAH mRNA expression increased over
the lifespan (ANOVA, F = 3.0, df = 6, 48, p = 0.02,
Figure 7D), with post-hoc LSD tests showing that FAAH
mRNA increased by 36% from neonates to young adult-
hood (p < 0.05).
Discussion
Here, we present evidence for dynamic and non-
concomitant changes in expression of mRNA for the
CB1R and the metabolic enzymes for its major ligands
during key epochs of human postnatal development
(Figure 8). During early postnatal life (the period from
neonate to toddlerhood), CB1R mRNA peaks in theDLPFC. Expression of the 2-AG synthetic (DAGLα) en-
zyme and the pre- and postsynaptic hydrolytic 2-AG
enzymes MGL and ABHD6 begins to increase. Expres-
sion of one of the anandamide synthetic enzymes
NAPE-PLD also increases steadily during early life while
mRNA for FAAH, the anandamide hydrolytic enzyme,
remains stable. At adolescence, CB1R mRNA is in de-
cline compared with early life, particularly in cortical
layer II. At this time, MGL has begun to decline while
ABHD6 mRNA is increasing, compared with early post-
natal life, suggesting an increased capacity for regulation
of postsynaptic 2-AG release. The potential for ananda-
mide turnover may increase in adolescence relative to
earlier life given the rise in NAPE-PLD and, to a lesser
extent, FAAH mRNA. By adulthood, CB1R mRNA is sig-
nificantly reduced from early life levels, suggesting at-
tenuation of control over synaptic neurotransmission
mediated by this receptor, coincident with maturation of
cognitive function. In contrast, the capacity for enzym-
atic control of anandamide turnover may continue to
rise in adulthood, indicated by high mRNA expression
of both NAPE-PLD and FAAH.
In situ hybridisation allowed us to determine the lam-
inar distribution of CB1R mRNA in the DLPFC. CB1R
mRNA is highest in cortical layer II in individuals aged
from one month to 50 years. We observed silver grains
indicative of CB1R mRNA expression densely clustered
over small, interneuron-like cells in layers II, III, IV and
VI and more sparsely collected over larger cells in layers
III, V and VI. CB1Rs in primate DLPFC are primarily
localised on CCK-positive inhibitory interneurons [16],
but are also co-localised with the calcium binding pro-
teins calbindin and calretinin in distinct subsets of cor-
tical inhibitory interneurons [16,18-20]. We did not
observe a correlation between CB1R and CCK mRNA,
which increases steadily from neonatal age to adulthood
[9]. However, CB1R mRNA expression was correlated
with both calbindin, which follows an inverted U-shaped
trajectory [9], and calretinin, which is highly expressed
Figure 6 (See legend on next page.)
Long et al. BMC Neuroscience 2012, 13:87 Page 6 of 14
http://www.biomedcentral.com/1471-2202/13/87
(See figure on previous page.)
Figure 6 DAGLα, MGL and ABHD6 mRNA in developing human DLPFC determined by microarray (A, C, E; y-axis, arbitrary units in log
scale) across age (x- axis, log years), qPCR [B, D, F; y-axis, mean (+ S.E.M.) expression normalised to the geometric mean of four
housekeeping genes] plotted by age group. * P <0.05, ** P <0.01, *** P <0.001 (ANOVA/ANCOVA and post-hoc LSD).
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[24], CCK [63,64] and calbindin mRNA [65] have been
detected in pyramidal neurons, expression data may re-
flect heterogeneous origins of the mRNA signal, such as
in layer V, which contains both pyramidal neurons and
wide arbor interneurons. Further studies quantifying
CB1R mRNA on specific cell types are necessary to re-
solve the developmental expression patterns of CB1R in
specific interneuron types.Figure 7 NAPE-PLD and FAAH mRNA in developing human DLPFC de
across age (x- axis, log years) and qPCR [B, D; y-axis, mean (+ S.E.M.)
housekeeping genes] plotted by age group. * P <0.05, ** P <0.01, *** PDevelopmental changes in CB1R mRNA
Peak CB1R mRNA expression was observed at neonatal
age by microarray but in toddlers by qPCR, a discrep-
ancy that may arise from the differential preference for
3’ versus 5’ transcript detection between the two techni-
ques. Laminar analysis of in situ hybridisation indicated
that CB1R mRNA expression peaks in neonates and
infants in most cortical layers. These findings are con-
firmed by recent data from a different study showing atermined by microarray (A, C; y-axis, arbitrary units in log scale)
expression normalised to the geometric mean of four
<0.001 (ANOVA/ANCOVA and post-hoc LSD).
Figure 8 Expression of mRNA for endocannabinoid receptor and metabolic enzymes across development. qPCR data in our tissue cohort
are represented schematically in the context of an inhibitory DLPFC synapse. Note that the size of each coloured mRNA reflects the relative
magnitude of expression at different developmental points, not absolute mRNA levels. Arrow thickness represents relative prominence of
signalling or enzymatic breakdown at each point. A Early life (neonate to toddler age) is characterised by robust potential for endocannabinoid
modification of presynaptic neurotransmission (suggested by moderate 2-AG synthesis, low levels of postsynaptic 2-AG hydrolysis, high CB1R
mRNA and low anandamide synthesis). B Adolescence is represented by increased potential for endocannabinoid modification of presynaptic
input (suggested by elevated 2-AG synthesis), but reduced potency of such endocannabinoid modification compared with early life (reflected by
reduced CB1R mRNA and increased anandamide synthesis). C By adulthood, modification of presynaptic neurotransmission by endocannabinoids
may be minimal: despite reduced presynaptic 2-AG hydrolysis, there may be reduced capacity for retrograde 2-AG signalling due to reduced
postsynaptic 2-AG synthesis and increased postsynaptic 2-AG hydrolysis, and CB1R mRNA is reduced. Anandamide turnover peaks at adulthood,
suggesting increased prominence in signalling at CB1R or other receptors such as TRPV1.
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CB1R mRNA peaking at neonatal age then decreasing
until adulthood [66].
The robust decrease in CB1R mRNA expression in
layer II from early life to adulthood in our human cohort
agrees with previous findings in primate [67] and sug-
gests strong regulation of neurotransmission by CB1Rs
early in life (Figure 8). It is tempting to speculate that
this CB1R down-regulation results in a gradual reduction
in CB1R-mediated suppression of inhibitory presynaptic
neurotransmission. Indeed, the first putative drop in
CB1R mRNA expression in layer II occurs around the
toddler/school age group, which represents a period of
increased inhibitory control in the prefrontal cortex
marked by dynamic changes in inhibitory interneuron
marker expression [9] and increased working memory
ability [68].
Endocannabinoids in early postnatal life
The shape of the postnatal trajectory of DAGLα mRNA
suggests that the capacity for synthesis of 2-AG, the
major cortical endocannabinoid, increases during early
postnatal life. In early life, 2-AG synthesis is also cata-
lysed by the beta isoform of DAGL, but since expression
of this isoform may decrease very early in postnatal life[38] it was not measured in the present study. 2-AG
tone is principally regulated by the presynaptic hydro-
lytic enzyme MGL [44], which showed reduced mRNA
expression over postnatal life after peaking in infancy,
and also by the postsynaptic enzyme ABHD6, expression
of which increased steadily from neonatal age to adult-
hood. In early development, MGL co-localises with
CB1Rs in presynaptic terminals of developing cortical
pyramidal neurons in order to regulate corticofugal axon
fasciculation [50]. Thus the role of MGL in controlling
2-AG availability may diminish once appropriate
cortical-origin connections are in place. Our results sug-
gest that the major endogenous ligand acting on the
CB1R, 2-AG, may be somewhat unstable early in human
life due to quite high variability in mRNA controlling
synthesis and breakdown within individuals less than
5 years of age. We suggest that 2-AG may be especially
influential and subject to increased regulation in early
postnatal life when the CB1R and presynaptic breakdown
enzyme for 2-AG are at developmentally high levels.
Endocannabinoids in adolescence
By adolescence there is a significant decrease in CB1R
expression, suggesting an overall decrease in sensitivity
to the effects of released endocannabinoids on
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performance reaches near adult levels with concomitant
increases in DLPFC activity recruitment [4,5]. However,
at adolescence, DAGLα has not started to decline and
MGL mRNA has just begun to decrease, while ABHD6
mRNA continues to increase, suggesting that capacity
for 2-AG hydrolysis in pre- and postsynaptic compart-
ments may be anatomically balanced at this age. Thus,
maintaining the earlier steady-state levels of 2-AG,
while incorporating more temporal/spatial control of
2-AG action in the face of CB1R down-regulation,
may be important during adolescence. This is an intri-
guing possibility and agrees with the increasing
endocannabinoid-mediated suppression of neurotrans-
mitter release observed in postnatal rat hippocampus
until early adolescence [52]. Taken together, our data
imply that the capacity for 2-AG signalling remains
fairly steady between early postnatal life and adoles-
cence then may decline. The gradual increase in ex-
pression at adolescence of the mRNA for anandamide
hydrolytic enzyme FAAH, which is localised postsy-
naptically [40], suggests that at this point there is
increased potential for control over the timing of ana-
ndamide availability for signalling at CB1R as well.
Endocannabinoids in adulthood
CB1R mRNA continues to decline until young adult-
hood, when individuals have attained mature levels of
inhibitory control over cortical excitability. Combined
with the early life increase in DAGLα and its decline in
adulthood (compared with toddlerhood, school age and
adolescence), our data is broadly consistent with previ-
ous work in the rat indicating that 2-AG is higher earlier
in postnatal life and declines with maturation [69]. As
maturation progresses the decline in DAGLα and MGL
and increase in ABHD6 mRNA reflect the potential for
reduction in the amount of 2-AG available for release
from the postsynaptic terminal as compared with early
postnatal life (Figure 8). Combined with reduced CB1R
expression at the same age, reduced 2-AG availability
after adolescence might ‘release’ the endocannabinoid-
mediated suppression of presynaptic neurotransmission
to allow greater inhibitory input to cortical circuitry.
Our data suggest an overall increase in the capacity for
anandamide synthesis via the NAPE-PLD pathway dur-
ing development and maturation of the human DLPFC.
Neonatal NAPE-PLD expression levels increase threefold
by adulthood, extending to humans previous findings of
increased cortical NAPE-PLD mRNA expression from
postnatal day 14 to 56 in rats [70] and suggesting that,
as in rat brain, anandamide synthesis may be higher in
maturity than in early life [69]. There are several pos-
sible functional implications of these observations. Ana-
ndamide induces long-term depression of inhibitorysynapses via transient receptor potential vanilloid 1
(TRPV1) receptors in hippocampus, striatum and devel-
oping midbrain [71-73], and since TRPV1 receptors are
expressed cortically [74] it is possible that anandamide
facilitates excitatory neurotransmission in this region in
a similar manner to its effects in the hippocampus.
However, if this were the case, then increased ananda-
mide signalling would be expected to result in decreased,
rather than increased inhibitory tone as maturation pro-
ceeds. On the other hand, anandamide opposes striatal
2-AG signalling by down-regulating 2-AG production
[75], suggesting the possibility that increased NAPE-PLD
expression results in greater synthetic capacity for ana-
ndamide production and consequent down-regulation of
2-AG production towards adulthood. Finally, our data
must be interpreted carefully in light of the other en-
zymatic pathways for anandamide synthesis, including
GDE1, ABHD4 and PTPN22. Future studies will benefit
from investigating the postnatal developmental expres-
sion of these mRNAs.
Conclusions
Overall, our data show that human early postnatal life,
adolescence and adulthood are characterised by distinct
differences in capacities for endocannabinoid synthesis,
breakdown and receptor expression, which we summar-
ise in Figure 8. While the varying circumstances sur-
rounding death and variable post-mortem intervals are
limitations of using human brain material, these factors
did not appear to obscure the major impact of age on
endocannabinoid system mRNAs nor did they have a
major impact on the measurements in our study. Our
findings may help to identify pathophysiological
mechanisms in developmental disorders characterised by
compromised cortical inhibitory function such as schizo-
phrenia [9,11,76,77] and autism [78]. For example, dis-
ruption of this dynamic postnatal maturation by
exogenous cannabinoid exposure might impact pro-
cesses such as cortical network oscillations, which are
governed by inhibitory interneuron activity and coordin-
ate behavioural processes such as discrimination during
decision-making [1] and have been reported to be sus-
ceptible to suppression by CB1R agonists [79,80]. Im-
portantly, since adolescence is the most likely period of
commencement of cannabis use, our findings emphasise
the need to determine how exposure to exogenous can-
nabis constituents such as THC during this period
affects the changes in the endocannabinoid system and
its role as a gatekeeper of neurotransmission.
Methods
Subjects
Tissue from the middle frontal gyrus of 69 cases aged
39 days to 49 years was obtained from the University of
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orders (NICHHD contract no. NO1=HD8-3283) follow-
ing informed consent from next of kin. This study was
carried out in accordance with the latest version of the
Declaration of Helsinki after review by the University of
NSW Human Research Ethics Committee (HREC
#07261). Cases were grouped and labelled according to
age, and demographic details of this cohort (Table 1)
have been described previously [81].
Total RNA isolation and RNA quality assessment
RNA isolation, quality assessment, microarray and qPCR
analyses were conducted following established protocols
[82]. Total RNA was extracted for microarray and qPCR
analysis from 300 mg gray matter using Trizol (Invitro-
gen, Carlsbad, California) according to the manufac-
turer’s instructions [83]. The quality of total RNA was
determined using the Agilent Bioanalyzer 2100 (Agilent
Technologies, Palo Alto, California). 100-200 ng RNA
was applied to an RNA 6000 Nano LabChip, without
heating prior to loading. The RNA integrity number
(RIN) was used as an indicator of RNA quality, ranging
from 1 – 10 (lowest - highest quality). Six samples wereTable 1 Summary of developmental cohort used for experime
Group Age (years) Gender pH
Microa
Neonate 0.11 - 0.24 2F, 5M 6.6
Infant 0.25 - 0.91 2F, 6M 6.6
Toddler 1.58 - 4.86 3F, 3M 6.7
School Age 7.84 - 12.97 3F, 3M 6.7
Teenage 16.34 - 17.82 1F, 4M 6.7
Young Adult 20.14 - 25.38 2F, 4M 6.7
Adult 35.99 - 49.22 2F, 4M 6.6
qPCR
Neonate 0.11 - 0.24 4F, 5M 6.5
Infant 0.25 - 0.91 5F, 8M 6.6
Toddler 1.58 - 4.86 4F, 4M 6.7
School Age 7.84 - 12.97 4F, 3M 6.6
Teenage 15 - 17.69 2F, 5M 6.7
Young Adult 20.14 - 25.38 3F, 6M 6.6
Adult 35.99 - 49.22 3F, 5M 6.6
In situ hybri
Neonate 0.11 - 0.24 4F, 5M 6.6
Infant 0.25 - 0.91 5F, 8M 6.6
Toddler 1.58 - 4.86 5F, 4M 6.7
School Age 7.84 - 12.97 4F, 3M 6.6
Teenage 15 - 17.69 2F, 4M 6.7
Young Adult 21.93 - 25.38 3F, 4M 6.6
Adult 35.99 – 48.69 1F, 4M 6.4excluded with RIN <5.2. Cases did not differ significantly
within each age group according to brain pH or RIN.
Microarray experimental design
Total RNA (n = 45) was purified through Qiagen RNA
miniKit columns (Qiagen Inc, Valencia, California)
according to the manufacturer’s protocol. Purified total
RNA was then prepared according to the Affymetrix
protocol [www.affymetrix.com [84]] and hybridised to
HG-U133 version 2.0+ (GeneChips, Affymetrix Califor-
nia). Hybridised arrays were subjected to rigorous qual-
ity control including analysis of 5’:3’ ratios (included
range 0.40-0.79), percent present (included range 37 -
47%), average pair-wise correlation analysis and principal
component analysis, resulting in the exclusion of 3 indi-
viduals. Affymetrix Microarray Suite (MAS 5.0) and the
Bioconductor package were used for image processing
and data normalisation respectively. Probe sets that were
50% present in at least one of the age subgroups were
retained in the analysis (33,210 probe sets retained; 61%
of total number). Microarray data are available in the




0 ± 0.05 22.71 ± 2.40 7.27 ± 0.18 7
9 ± 0.05 17.63 ± 2.72 7.57 ± 0.17 8
4 ± 0.07 25.67 ± 3.90 6.91 ± 0.24 6
3 ± 0.06 14.67 ± 2.22 7.03 ± 0.31 6
5 ± 0.05 18.40 ± 2.16 6.26 ± 0.53 5
5 ± 0.07 12.00 ± 2.21 6.91 ± 0.24 6
8 ± 0.09 13.83 ± 2.18 6.78 ± 0.25 6
6 ± 0.05 22.11 ± 1.88 7.01 ± 0.27 9
1 ± 0.05 17.46 ± 1.76 7.19 ± 0.19 13
7 ± 0.06 19.25 ± 1.89 6.85 ± 0.25 8
9 ± 0.07 14.43 ± 1.95 6.88 ± 0.24 7
4 ± 0.03 17.86 ± 1.47 6.60 ± 0.28 7
7 ± 0.08 13.67 ± 2.75 6.73 ± 0.22 9
0 ± 0.10 13.38 ±1 .63 6.53 ± 0.27 8
disation
0 ± 0.05 22.11 ± 1.88 7.01 ± 0.27 9
1 ± 0.05 17.46 ± 1.76 7.20 ± 0.19 13
4 ± 0.06 22.00 ± 3.22 6.83 ± 0.22 9
9 ± 0.07 14.43 ± 1.95 6.88 ± 0.24 7
5 ± 0.04 16.67 ± 1.02 6.64 ± 0.33 6
7 ± 0.09 14.43 ± 3.20 6.83 ± 0.25 7
5 ± 0.10 12.60 ± 1.60 6.39 ± 0.35 5
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Results from the microarray experiment were con-
firmed using qPCR (n = 61). cDNA was synthesised in
3 reactions of 3 μg of total RNA using the Superscript
First-Strand Synthesis Kit (Invitrogen) according to the
manufacturer’s protocol. Pre-designed TaqMan Gene
Expression Assays (Applied Biosystems, Foster City,
California) were chosen for the CB1R (CNR1;
Hs00275634_m1), the 2-AG synthesising enzyme diacyl-
glycerol lipase alpha (DAGLα, Hs00391374_m1), the 2-
AG inactivating enzymes monoglyceride lipase (MGL,
Hs00200752_m1) and abhydrolase domain containing 6
(ABHD6, Hs0097789_m1), the anandamide synthesizing
enzyme N-acylphosphatidylethanolamine phospholipase
D (NAPE-PLD, Hs00419593_m1) and the anandamide
inactivating enzyme fatty acid amide hydrolase (FAAH,
Hs00155015_m1). qPCR was performed with an ABI
Prism 7900HT Fast real-time PCR system with a 384-
well format. Measurements were performed in triplicate
and relative quantities determined from a seven-point
standard curve. Control wells containing no cDNA tem-
plate displayed no amplification. Efficiencies of the qPCR
reactions ranged from 80% to 100%, and r2 values were
between 0.97 and 1.00. Outliers were excluded from
qPCR analysis if their normalised expression values
were greater than 2 standard deviations from the
group mean. Expression levels were normalised to the
geometric mean of four ‘housekeeper’ genes that did
not change expression with development: hydroxy-
methylbilane synthase (HMBS, Hs00609297_m1),
glucuronidase-b (GUSB, Hs99999908_m1), ubiquitin C
(UBC, Hs00824723_m1) and cyclophilin A (PPIA,
Hs99999904_m1) [81].
Riboprobe design
A 247 bp fragment of the human CNR1 gene cDNA,
corresponding to bps 937–1183, was inserted into a
pCRII vector (Invitrogen, CA, USA). Antisense ribop-
robes and sense strand RNAs were generated from line-
arised plasmid using SP6 and T7 polymerases
respectively and an in vitro transcription kit as recom-
mended by the manufacturer (Promega, WI, USA). [35S]
antisense and sense riboprobes were labelled to a spe-
cific activity of ~2 x 109 cpm/μg by addition of radiola-
belled UTP and were purified by ethanol precipitation.
In situ hybridisation
14-μm coronal sections of the middle frontal gyrus
from the developmental cohort tissue were used
(n = 56). In situ hybridisation histochemistry was per-
formed as previously described [85], using two slides
per case. After hybridisation and washing steps, sec-
tions were exposed to autoradiographic film (Bio-Max,
Kodak) for 3 weeks. Sections were then dipped inphotographic emulsion (Kodak, type II NTB) for
13 weeks and then developed and counterstained with
thionine. All sections were assayed together to limit
interassay variability.Image analysis
Calibrated densitometric analysis (ImageJ, National
Institutes of Health, http://rsb.info.nih.gov/ij/) was con-
ducted, blind to age, on Brodmann’s area 46 of the
DLPFC delineated microscopically from adjacent Nissl-
stained sections. For each section, three randomly placed
lines (415 μm width) were drawn perpendicular to the
pial surface, traversing the entire cortical grey matter.
The density of CB1R mRNA as a function of cortical
depth was computed from continuous optical density
measurements recorded along the length of these lines,
using radioactive standards for comparison (American
Radiolabeled Chemicals Inc., MO, USA). The percentage
of full cortical width corresponding to the individual
lamina was determined from published guidelines as fol-
lows: I (2-6%), II (14-18%), III (20-42%), IV (46-50%), V
(54-68%) and VI (72-92%) [86,87].Statistical analysis
Normalisation and analysis of microarray data were per-
formed using R (www.r-project.org) and Bioconductor
software (www.bioconductor.org), with which differen-
tial gene expression across chronological age was ana-
lysed using linear regression. The R program was used
to draw regression lines of best fit depending on the
profile of gene expression changes with age. qPCR and
in situ hybridisation data were analysed using PASW
Statistics 18 (SPSS Inc., IL, USA). Differences in nor-
malised mRNA expression detected by qPCR were
tested with one-way analysis of variance (ANOVA) with
age group as the grouping variable in all analyses. Pear-
son’s correlation analyses were performed on normal-
ised qPCR mRNA expression and demographic
variables, and analysis of covariance (ANCOVA) was
conducted where significant correlations were observed
with pH, post-mortem interval (PMI) and RIN as con-
tinuous variables. Differences in optical density of CB1R
mRNA detected by in situ hybridisation were tested
with two-way repeated measures ANOVA with age
group as the between-subjects variable and cortical
layer as the within-subjects variable. Fisher’s least sig-
nificant difference (LSD) post-hoc analyses were used to
identify significant differences between age groups. Sim-
ple linear regression was performed to identify predict-
ive relationships between normalised expression of
CB1R mRNA detected by qPCR and interneuron mar-
ker mRNAs of interest that were previously measured
in the same cohort [9].
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Additional file 1: Figure S1. Geometric mean of expression of HMBS,
GUSB, UBC and PPIA mRNA in human DLPFC determined by qPCR [y-axis,
mean (+ S.E.M.)] expression plotted by age group. n = 7 – 13.
Additional file 2: Figure S2. Representative autoradiograms from
sections from two school-aged individuals showing A CB1R mRNA
hybridisation after antisense strand riboprobe incubation and Bnegligible
CB1R mRNA hybridisation after sense strand riboprobe incubation.
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